Saturday , January 22 2022

Researchers make possible treatment for peanut allergy News


Nutshell and shell kernel


Participants could study tolerating 100 percent more nuts at the end of the study than they did at the beginning

Children and young people with peanut allergy may be able to protect themselves from accidental assault by building their tolerance to peanut protein over time, a study published in the Journal Journal of Medicine New England (November 18, 2018) has shown[1].

The stage III test, presented at the annual Allergy College, Asthma and Immunology College (ACAAI) scientific meeting, comprised 551 participants aged 4-55, all of which were a real allergy to nuts. Random participants were given in a ratio of 3: 1 to accept either AR101 (a biological drug that results in seeds with a typical protein profile) or placebo.

The AR101 group received increasing amounts of nutshell protein until they reach the "maintenance dose" of 300mg, which is equivalent to one peanut every day, and then they wait for about 24 weeks.

The researchers then tested to see if the participants can give a challenge of 600mg or more – which corresponds to about two nut nut kernels – without symptoms of dose restriction.

In general, 67% of participants between the ages of 4 and 17 in the AR101 group could tolerate one dose of 600mg of at least at least at least at the end of the study, compared to 4% in the placebo group , although no-one could tolerate more than 30mg of nutshell protein before the procedure.

"Responses of oral challenges at the end of the study were much less than before the treatment," said Stephen Tilles, studying ACAAI co-authorship and vice president.

"On average, participants were able to tolerate a dose of 100 more nuts at the end of the study than they did at the beginning. In addition, the symptoms caused by the higher 100-fold dose at the end of the study were more expensive than & # 39; the symptoms are lower at the beginning of the study. "

However, there was no significant impact in the participants aged between 18 and 55.

Damaging incidents were common in both probation groups. But adverse events considered by the researchers have been serious or serious in less than 6% of participants in the AR101 group and in fewer than 2% of those in the placebo group.

"This is not a quick solution, and it does not mean that people with peanut allergy can eat nuts whenever they want," said Jay Lieberman, co-authored and vice chair of the ACAAI Food Allergy Committee.

"But it's definitely a development. It is hoped that treatment would be available in the second half of 2019. If that happens, people who accept and be able to tolerate this treatment should be protected from accidental exposures. "

If this procedure is approved by the FDA, it will be available through prescription, and people with peanut allergy will need to be taken continuously to be accidentally protected from accident, the researchers said.

Name: The Pharmaceutical Journal

DOI: 10.1211 / PJ.2018.20205773

Source link